← Back to Clinical Trials
Recruiting NCT07626944

NCT07626944 Effects of Binaural Beats and Spatialized Music on Behavioural and Psychological Symptoms of Dementia in Assisted Living Facility Residents

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07626944
Status Recruiting
Phase
Sponsor Maharishi International University
Condition BPSD
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2026-05-04
Primary Completion 2026-06-27

Eligibility & Interventions

Sex All sexes
Min Age 55 Years
Max Age 95 Years
Study Type INTERVENTIONAL
Interventions
Personalized Music Listening (PML)Binaural Beat Music (BBM)Spatialized Music (SM)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2026-05-04 with a primary completion date of 2026-06-27.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to investigate the effects of Binaural Beat Music (BBM; personalized music playlist with binaural beats), Spatialized Music (SM; personalized and spatialized music playlist), their combination, and possible interaction on older adults in an assisted living community who are either living with a dementia diagnosis or are experiencing typical age-related changes. The control condition is a personalized music playlist without binaural beats and spatialization. It is hypothesized that BBM, SM, and their combination each improve aspects of BPSD compared to controls over a two-week intervention period. The Specific Aims of the study are (1) to evaluate whether BBM, SM, and/or their combination is superior to control in reducing BPSD severity (primary outcome); (2) to evaluate whether BBM, SM, and/or their combination is superior to control in reducing caregiver distress (secondary outcomes); and (3) to evaluate the effects of BBM, SM, and/or their combination on improving overall well-being and mood (secondary outcomes).

Eligibility Criteria

Inclusion Criteria: * (1) age 55-95 years; (2) the subject and/or his/her legal guardian have signed written informed consent; (3) the subject is able to complete the entire trial period; and (4) a minimum of fifty percent of the subjects will have a diagnosis of a dementia condition with a moderate to severe progression. Exclusion Criteria: * (1) profound hearing loss or impairment; (2) history of seizures, epilepsy (especially sound-induced epilepsy), claustrophobia, or other conditions that put the subject at risk during the trial; (3) physical or mental conditions that may result in inability to complete and/or affect the efficacy of assessment.

Contact & Investigator

Central Contact

Paul Oomen, MMus

✉ poomen@nemolabs.info

📞 +36203980356

Frequently Asked Questions

Who can join the NCT07626944 clinical trial?

This trial is open to participants of all sexes, aged 55 Years or older, up to 95 Years, studying BPSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07626944 currently recruiting?

Yes, NCT07626944 is actively recruiting participants. Contact the research team at poomen@nemolabs.info for enrollment information.

Where is the NCT07626944 trial being conducted?

This trial is being conducted at Denver, United States, Lakewood, United States.

Who is sponsoring the NCT07626944 clinical trial?

NCT07626944 is sponsored by Maharishi International University. The trial plans to enroll 120 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology